Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
stocks
Most popular shares in SMSFs
stocks
Will China strong arm BHP into lower iron ore prices?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,183.30 | 72.50 | -0.78% |
| CAC 40 | 7,937.90 | 19.90 | 0.25% |
| DAX 40 | 24,305.69 | 64.23 | 0.26% |
| Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
| FTSE 100 | 9,421.59 | 87.81 | -0.92% |
| HKSE | 25,889.48 | 863.11 | -3.23% |
| NASDAQ | 22,204.43 | 820.20 | -3.56% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,351.92 | 218.94 | -1.61% |
| S&P 500 | 6,552.51 | 182.60 | -2.71% |
| S&P/ASX 200 | 8,882.80 | 66.30 | -0.74% |
| SSE Composite Index | 3,889.50 | 7.53 | -0.19% |